Anaemia+1
RecruitingA Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions
A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions
- Disease:AnaemiaMyelodysplastic syndrome
- Substances:ElriterceptEpoetin Alfa
Poland- Participants:18–64 years · 65+ years
- Substances:Elritercept
- Sponsor:Takeda Development Center Americas Inc.










